Cover Image
市場調查報告書

美國的靜脈通路裝置、配件市場概要

US Market Overview for Vascular Access Devices and Accessories 2016 - MedView

出版商 iData Research Inc. 商品編碼 360590
出版日期 內容資訊 英文 203 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的靜脈通路裝置、配件市場概要 US Market Overview for Vascular Access Devices and Accessories 2016 - MedView
出版日期: 2016年01月05日 內容資訊: 英文 203 Pages
簡介

美國的靜脈通路裝置、配件市場,2015年增大。今後,也預計持續成長。

本報告提供美國的靜脈通路裝置、配件市場相關調查分析,疾病概要,產品的評估,市場概要相關的系統性資訊。

第1章 摘要整理

第2章 調查手法

第3章 疾病概要

  • 基本結構
  • 血管病變、障礙
  • 患者的人口統計
    • 癌症
    • 末期腎功能衰竭
    • 糖尿病

第4章 產品的評估

  • 產品系列
    • 置入式埠口
    • Port Needle
    • 中央靜脈導管 (CVC)
    • 末梢穿刺中央靜脈導管 (PICC)
    • 週邊靜脈導管 (PIVC)
    • 透析用導管
    • 超音波靜脈通路裝置
    • 導管固定器具
    • 注射器、針

第5章 美國的靜脈通路裝置、配件市場概要

  • 市場概要
  • 趨勢分析
  • 推動因素、阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析
  • 企業簡介
    • 3M
    • AngioDynamics
    • Becton Dickinson
    • C.R. Bard
    • FUJIFILM SonoSite, Inc.
    • GE Healthcare
    • Johnson & Johnson
    • Medcomp
    • Medtronic
    • Smith & Nephew
    • Smiths Medical
    • Teleflex Medical
  • SWOT分析
  • M&A

圖表

目錄
Product Code: iDATA_USVA16_MV

The majority of vascular access devices are single-use disposables. These devices can be of high volume and low cost or of relatively low volume and high cost. Syringes and needles, catheter stabilization devices and ultrasound systems are all used in various non-vascular access applications. Therefore, only the portion of those segments directly involved in vascular access was included in the overall market.

The U.S. market for vascular access devices and accessories increased in 2015 and growth is expected to persist throughout the forecast period. Market growth will be driven by government policies that encourage safer practices and products, including those introduced by the Centers for Disease Control and Prevention (CDC) and the Occupational Safety and Health Administration (OSHA).

As a result of these policies, treatments for vascular access-related bloodstream infections are no longer reimbursable, thereby increasing the need for antimicrobial and antibacterial devices. Moreover, guidelines by the Joint Commission outlined the increased use of full barrier drapes and manufactured catheter securement devices (MCSDs) to reduce the risk of infection, both of which are becoming more prevalent in catheter kits.

New products in the ultrasound and tip-location markets will also drive the vascular access market, as standards of care shift away from doctors and toward nurses placing the catheters. With these new technologies, catheter placement can be done at bedside with fewer incidences of catheter movement, or malposition. In addition, nearly all patients admitted to the hospital are treated with vascular access devices. With the aging U.S. population, the demand for vascular access products will rise.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1. U.S. VASCULAR ACCESS DEVICES AND ACCESSORIES MARKET OVERVIEW
  • 1.2. COMPETITIVE LANDSCAPE
  • 1.3. MARKET TRENDS
  • 1.4. KEY MARKET DEVELOPMENTS
  • 1.5. MARKETS INCLUDED
  • 1.6. PROCEDURES INCLUDED
  • 1.7. PROCEDURE CODES INVESTIGATED
  • 1.8. KEY REPORT UPDATES
  • 1.9. VERSION HISTORY

RESEARCH METHODOLOGY

  • 2.1. RESEARCH SCOPE
  • 2.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 3.1. BASIC ANATOMY
    • 3.1.1. Human Vascular System
  • 3.2. VASCULAR PATHOLOGY AND DISORDERS
    • 3.2.1. Cancer
    • 3.2.2. End-Stage Renal Disease
    • 3.2.3. Diabetes
  • 3.3. PATIENT DEMOGRAPHICS
    • 3.3.1. Cancer
      • 3.3.1.1. Digestive Cancer
      • 3.3.1.2. Genital Cancer
      • 3.3.1.3. Breast Cancer
      • 3.3.1.4. Respiratory Cancer
      • 3.3.1.5. Urinary Cancer
      • 3.3.1.6. Skin Cancer
      • 3.3.1.7. Lymphoma
      • 3.3.1.8. Endocrine System Cancer
      • 3.3.1.9. Leukemia
      • 3.3.1.10. Oral Cavity/Larynx
      • 3.3.1.11. Myeloma
      • 3.3.1.12. Brain/Other Nervous System
      • 3.3.1.13. Soft Tissue (including heart)
      • 3.3.1.14. Bones and Joints
      • 3.3.1.15. Eye and Orbit
    • 3.3.2. End-Stage Renal Disease
      • 3.3.2.1. End-Stage Renal Disease Incidence
        • 3.3.2.1.1. End-Stage Renal Disease Incident Cases by Modality
        • 3.3.2.1.2. End-Stage Renal Disease Incident Cases by Age Group
        • 3.3.2.1.3. End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy
      • 3.3.2.2. Vascular Access Use at Hemodialysis Initiation
        • 3.3.2.2.1. Vascular Access Use During First Year of Hemodialysis
          • 3.3.2.2.1.1. Vascular Access Use During First Year of Hemodialysis by Age Group
          • 3.3.2.2.1.2. Vascular Access Use During First Year of Hemodialysis by Sex End-Stage
        • 3.3.2.3. Stage Renal Disease Prevalence
          • 3.3.2.3.1. End-Stage Renal Disease Prevalent Cases by Modality
            • 3.3.2.3.1.1. Prevalent Hemodialysis Patients by Vascular Access Type
          • 3.3.2.3.2. End-Stage Renal Disease Prevalent Cases by Age Group
          • 3.3.2.3.3. End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy
    • 3.3.3. Diabetes
      • 3.3.3.1. Diagnosed Diabetes Incidence Amongst Adults
        • 3.3.3.1.1. Diagnosed Diabetes Incidence Amongst Adults by State
      • 3.3.3.2. Diagnosed Diabetes Prevalence Amongst Adults
        • 3.3.3.2.1. Diagnosed Diabetes Prevalence Amongst Adults by Medication Status
        • 3.3.3.2.2. Diagnosed Diabetes Prevalence Amongst Adults by State and Age Group
        • 3.3.3.2.3. Diagnosed Diabetes Prevalence Amongst Adults by State and Gender

PRODUCT ASSESSMENT

  • 4.1. PRODUCT PORTFOLIOS
    • 4.1.1. Implantable Port Devices
      • 4.1.1.1. Introduction
        • 4.1.1.1.1. Implantable Port Patients
        • 4.1.1.1.2. Port Implantation Procedures
        • 4.1.1.1.3. Port Infusion
        • 4.1.1.1.4. Port Maintenance
    • 4.1.2. Port Needles
      • 4.1.2.1. Introduction
    • 4.1.3. Central Venous Catheters
      • 4.1.3.1. Introduction
        • 4.1.3.1.1. CVC Procedures
        • 4.1.3.1.2. CVC Kits
        • 4.1.3.1.3. CVC Market Segments
    • 4.1.4. Peripherally Inserted Central Catheters
      • 4.1.4.1. Introduction
        • 4.1.4.1.1. PICC Placement
    • 4.1.5. Peripheral Intravenous Catheters
      • 4.1.5.1. Introduction
    • 4.1.6. Dialysis Catheters
      • 4.1.6.1. Introduction
        • 4.1.6.1.1. AV Fistulae
        • 4.1.6.1.2. AV Grafts
        • 4.1.6.1.3. Dialysis Catheters
    • 4.1.7. Ultrasound Vascular Access Devices
      • 4.1.7.1. Introduction
        • 4.1.7.1.1. Alternates to Ultrasound Guidance
        • 4.1.7.1.2. Ultrasound Guidance
        • 4.1.7.1.3. Ultrasound Vessel Mapping
        • 4.1.7.1.4. Tip Location
        • 4.1.7.1.5. General Ultrasound Imaging Systems with Vascular Access Guidance Capabilities Market 131
    • 4.1.8. Catheter Securement Devices
      • 4.1.8.1. Introduction
        • 4.1.8.1.1. Catheter Stabilization Methods
    • 4.1.9. Syringe and Needles
      • 4.1.9.1. Introduction

U.S. VASCULAR ACCESS DEVICE AND ACCESSORIES MARKET OVERVIEW

  • 5.1. MARKET OVERVIEW
  • 5.2. TREND ANALYSIS
  • 5.3. DRIVERS AND LIMITERS
    • 5.3.1. Market Drivers
    • 5.3.2. Market Limiters
  • 5.4. COMPETITIVE MARKET SHARE ANALYSIS
  • 5.5. COMPANY PROFILES
    • 5.5.1. 3M
    • 5.5.2. AngioDynamics
    • 5.5.3. Becton Dickinson
    • 5.5.4. C.R. Bard
    • 5.5.5. FUJIFILM SonoSite, Inc.
    • 5.5.6. GE Healthcare
    • 5.5.7. Johnson & Johnson
    • 5.5.8. Medcomp
    • 5.5.9. Medtronic
    • 5.5.10. Smith & Nephew
    • 5.5.11. Smiths Medical
    • 5.5.12. Teleflex Medical
  • 5.6. SWOT ANALYSIS
    • 5.6.1. Becton Dickinson
    • 5.6.2. C.R. Bard
    • 5.6.3. FUJIFILM SonoSite, Inc.
    • 5.6.4. GE Healthcare
    • 5.6.5. Medtronic
    • 5.6.6. Smiths Medical
    • 5.6.7. Teleflex Medical
  • 5.7. MERGERS AND ACQUISITIONS
    • 5.7.1. Teleflex Acquires Nostix, LLC
    • 5.7.2. The Vygon Group Acquires Perouse Medical
    • 5.7.3. Roundtable Healthcare Partners Acquires TIDI Products
    • 5.7.4. C.R. Bard Acquires Vascular Pathways, Inc.
    • 5.7.5. 3M Acquires Ivera Medical Corporation
    • 5.7.6. Medtronic Acquires Covidien
    • 5.7.7. TIDI Products Acquires Catheter Securement Business from Zefon International
    • 5.7.8. AngioDynamics Acquires Rights to Celerity™ System from Medcomp
    • 5.7.9. C.R. Bard Acquires PICC Technology from 3DT Holdings LLC
    • 5.7.10. Becton Dickinson Acquires Safety Syringes Inc.
    • 5.7.11. Endeavor Capital Acquires Access Scientific, Inc.
    • 5.7.12. Teleflex Medical Acquires Semprus BioSciences
    • 5.7.13. AngioDynamics Acquires Navilyst Medical
    • 5.7.14. Vygon Signs Distribution Agreement with Ambu Inc.
    • 5.7.15. Fujifilm Holdings Corporation Acquires SonoSite, Inc.
    • 5.7.16. VeriTeQ Acquisition Corp. Acquires VeriChip™ Technology from PositiveID Corp.

LIST OF CHARTS

  • Chart 0-1: Vascular Access Device Market by Segment, U.S., 2012-2022
  • Chart 0-2: Vascular Access Device Market Overview, U.S., 2015 and 2022
  • Chart 3-1: Male Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-2: Male Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-3: Female Incidence, Digestive Cancer, U.S., 2016
  • Chart 3-4: Female Deaths, Digestive Cancer, U.S., 2016
  • Chart 3-5: Male Incidence, Genital Cancer, U.S., 2016
  • Chart 3-6: Male Deaths, Genital Cancer, U.S., 2016
  • Chart 3-7: Female Incidence, Genital Cancer, U.S., 2016
  • Chart 3-8: Female Deaths, Genital Cancer, U.S., 2016
  • Chart 3-9: Incidence by Gender, Breast Cancer, U.S., 2016
  • Chart 3-10: Deaths by Gender, Breast Cancer, U.S., 2016
  • Chart 3-11: Male Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-12: Male Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-13: Female Incidence, Respiratory Cancer, U.S., 2016
  • Chart 3-14: Female Deaths, Respiratory Cancer, U.S., 2016
  • Chart 3-15: Male Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-16: Male Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-17: Female Incidence, Urinary Cancer, U.S., 2016
  • Chart 3-18: Female Deaths, Urinary Cancer, U.S., 2016
  • Chart 3-19: Male Incidence, Skin Cancer, U.S., 2016
  • Chart 3-20: Male Deaths, Skin Cancer, U.S., 2016
  • Chart 3-21: Female Incidence, Skin Cancer, U.S., 2016
  • Chart 3-22: Female Deaths, Skin Cancer, U.S., 2016
  • Chart 3-23: Male Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-24: Male Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-25: Female Incidence, Lymphoma Cancer, U.S., 2016
  • Chart 3-26: Female Deaths, Lymphoma Cancer, U.S., 2016
  • Chart 3-27: Male Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-28: Male Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-29: Female Incidence, Endocrine Cancer, U.S., 2016
  • Chart 3-30: Female Deaths, Endocrine Cancer, U.S., 2016
  • Chart 3-31: Male Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-32: Male Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-33: Female Incidence, Leukemia Cancer, U.S., 2016
  • Chart 3-34: Female Deaths, Leukemia Cancer, U.S., 2016
  • Chart 3-35: Male Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-36: Male Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-37: Female Incidence, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-38: Female Deaths, Oral Cavity/Larynx Cancer, U.S., 2016
  • Chart 3-39: Incidence by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-40: Deaths by Gender, Myeloma Cancer, U.S., 2016
  • Chart 3-41: Incidence by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-42: Deaths by Gender, Brain/Other Nervous System Cancer, U.S., 2016
  • Chart 3-43: Incidence by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-44: Deaths by Gender, Soft Tissue Cancer, U.S., 2016
  • Chart 3-45: Incidence by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-46: Deaths by Gender, Bone and Joint Cancers, U.S., 2016
  • Chart 3-47: Incidence by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-48: Deaths by Gender, Eye and Orbit Cancers, U.S., 2016
  • Chart 3-49: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Chart 3-50: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Chart 3-51: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Chart 3-52: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015 83
  • Chart 3-53: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Chart 3-54: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Chart 3-55: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Chart 3-56: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Chart 3-57: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Chart 3-58: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Chart 3-59: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Chart 3-60: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Chart 3-61: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Chart 4-1: Central Venous Catheter Market Segments, U.S., 2015
  • Chart 5-1: Total Vascular Access Device Market, U.S., 2012-2022
  • Chart 5-2: Vascular Access Devices and Accessories Market by Segment, U.S., 2012-2022
  • Chart 5-3: Vascular Access Devices and Accessories Market Breakdown, U.S., 2015
  • Chart 5-4: Vascular Access Devices and Accessories Market Breakdown, U.S., 2022
  • Chart 5-5: Growth Rates by Segment, Vascular Access Devices and Accessories Market, U.S., 2012-2022
  • Chart 5-6: Leading Competitors, Vascular Access Device Market, U.S., 2015

LIST OF FIGURES

  • Figure 0-1: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (1 of 2)
  • Figure 0-2: Vascular Access Device and Accessories Competitor Market Share Ranking by Segment, U.S., 2015 (2 of 2)
  • Figure 0-3: Companies Researched in Report, U.S., 2015
  • Figure 0-4: Factors Impacting the Vascular Access Device and Accessories Market by Segment, U.S.
  • Figure 0-5: Recent Events in the Vascular Access Device and Accessories Market, U.S., 2012-2015
  • Figure 0-6: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (1 of 3)
  • Figure 0-7: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (2 of 3)
  • Figure 0-8: Vascular Access Devices & Accessories Markets Covered, U.S., 2015 (3 of 3)
  • Figure 0-9: Vascular Access Devices & Accessories Procedures Covered, U.S., 2015
  • Figure 0-10: Procedural Codes, U.S., 2015
  • Figure 0-11: Key Report Updates, U.S., 2014 and 2016 (1 of 2)
  • Figure 0-12: Key Report Updates, U.S., 2014 and 2016 (2 of 2)
  • Figure 0-13: Version History
  • Figure 3-1: Digestive Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-2: Genital Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-3: Breast Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-4: Respiratory Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-5: Urinary Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-6: Skin Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-7: Lymphoma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-8: Endocrine Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-9: Leukemia Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-10: Oral Cavity/Larynx Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-11: Myeloma Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-12: Brain/Other Nervous System Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-13: Soft Tissue (Including Heart) Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-14: Bone and Joint Cancer Statistics by Type and Gender, U.S., 2016
  • Figure 3-15: Eye and Orbit Statistics by Type and Gender, U.S., 2016
  • Figure 3-16: End-Stage Renal Disease Incident Cases, U.S., 1996-2015
  • Figure 3-17: End-Stage Renal Disease Incident Cases by Modality, U.S., 1996-2015
  • Figure 3-18: End-Stage Renal Disease Incident Cases by Age Group, U.S., 1996-2015
  • Figure 3-19: End-Stage Renal Disease Incident Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-20: Vascular Access Use at Hemodialysis Initiation, U.S., 2005-2015
  • Figure 3-21: Vascular Access Use During First Year of Hemodialysis, U.S., 2013-2014
  • Figure 3-22: Vascular Access Use During First Year of Hemodialysis by Age Group, U.S., 2013-2014
  • Figure 3-23: Vascular Access Use During First Year of Hemodialysis by Sex, U.S., 2013-2014
  • Figure 3-24: End-Stage Renal Disease Prevalent Case Count, U.S., 1996-2015
  • Figure 3-25: End-Stage Renal Disease Prevalent Cases by Modality, U.S., 1996-2015
  • Figure 3-26: Prevalent Hemodialysis Patients by Vascular Access Type, U.S., 2003-2015
  • Figure 3-27: End-Stage Renal Disease Prevalent Cases by Age Group, U.S., 1996-2015
  • Figure 3-28: End-Stage Renal Disease Prevalent Cases Using Home Dialysis by Therapy, U.S., 1996-2015
  • Figure 3-29: Diagnosed Diabetes Incidence Count Adults, U.S., 1997-2015
  • Figure 3-30: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (1 of 2)
  • Figure 3-31: Diagnosed Diabetes Incidence Age-Adjusted Rate per 1000 Adults by State, U.S., 2014 (2 of 2)
  • Figure 3-32: Diagnosed Diabetes Prevalence Count Adults, U.S., 1997-2015
  • Figure 3-33: Diagnosed Diabetes Prevalence Count Adults by Medication Status, U.S., 1997-2015
  • Figure 3-34: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (1 of 2)
  • Figure 3-35: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Age Group, U.S., 2014 (2 of 2)
  • Figure 3-36: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (1 of 2)
  • Figure 3-37: Diagnosed Diabetes Prevalence Age-Adjusted Rate per 100 Adults by State and Gender, U.S., 2014 (2 of 2)
  • Figure 5-1: Total Vascular Access Device Market, U.S., 2012-2022 (US$M)
  • Figure 5-2: Vascular Access Devices and Accessories Market by Segment, U.S., 2012-2022 (US$M) (1 of 2)
  • Figure 5-3: Vascular Access Devices and Accessories Market by Segment, U.S., 2012-2022 (US$M) (2 of 2)
  • Figure 5-4: Growth Rates by Segment, Vascular Access Devices and Accessories Market, U.S., 2012-2022 (1 of 2)
  • Figure 5-5: Growth Rates by Segment, Vascular Access Devices and Accessories Market, U.S., 2012-2022 (2 of 2)
  • Figure 5-6: Drivers and Limiters, Vascular Access Devices and Accessories Market, U.S., 2015
  • Figure 5-7: Leading Competitors, Vascular Access Device Market, U.S., 2015 (1 of 2)
  • Figure 5-8: Leading Competitors, Vascular Access Device Market, U.S., 2015 (2 of 2)
  • Figure 5-9: SWOT Analysis, Becton Dickinson, 2015
  • Figure 5-10: SWOT Analysis, C.R. Bard, 2015
  • Figure 5-11: SWOT Analysis, FUJIFILM SonoSite, Inc., 2015
  • Figure 5-12: SWOT Analysis, GE Healthcare, 2015
  • Figure 5-13: SWOT Analysis, Medtronic, 2015
  • Figure 5-14: SWOT Analysis, Smiths Medical, 2015
  • Figure 5-15: SWOT Analysis, Teleflex Medical, 2015
Back to Top